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Background: Malaria elimination remains a priority research agenda with the need for
interventions that reduce and/or block malaria transmission from humans to mosquitoes.
Transmission-blocking vaccines (TBVs) are in development, most of which target
the transmission stage (i.e., gametocyte) antigens Pfs230 and Pfs48/45. For these
interventions to be implemented, there is a need to understand the naturally acquired
immunity to gametocytes. Several studies have measured the prevalence of immune
responses to Pfs230 and Pfs48/45 in populations in malaria-endemic areas.
Methods: We conducted a systematic review of studies carried out in African
populations that measured the prevalence of immune responses to the gametocyte
antigens Pfs230 and Pfs48/45. We assessed seroprevalence of antibody responses to
the two antigens and investigated the effects of covariates such as age, transmission
intensity/endemicity, season, and parasite prevalence on the prevalence of these
antibody responses by meta-regression.
Results: We identified 12 studies covering 23 sites for inclusion in the analysis. We
found that the range of reported seroprevalence to Pfs230 and Pfs48/45 varied widely
across studies, from 0 to 64% for Pfs48/45 and from 6 to 72% for Pfs230. We also found
a modest association between increased age and increased seroprevalence to Pfs230:
adults were associated with higher seroprevalence estimates in comparison to children
(β coefficient 0.21, 95%CI: 0.05–0.38, p= 0.042). Methodological factors were the most
significant contributors to heterogeneity between studies which prevented calculation of
pooled prevalence estimates.
Conclusions: Naturally acquired sexual stage immunity, as detected by antibodies to
Pfs230 and Pfs48/45, was present in most studies analyzed. Significant between-study
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heterogeneity was seen, and methodological factors were a major contributor to
this, and prevented further analysis of epidemiological and biological factors. This
demonstrates a need for standardized protocols for conducting and reporting
seroepidemiological analyses.
Keywords: immunity, Plasmodium falciparum, gametocytes, Pfs230, Pfs48/45
INTRODUCTION
Progress has been made in controlling malaria with marked
reductions in the global disease burden reported from 2000
onwards (1, 2). However, the 2018 World Malaria Report
indicates stalling progress in malaria control in the past two
years (1) which threatens the gains made in malaria control
and hence efforts to develop new methods to control malaria
must remain a priority. Vector control and treatment of acute
malaria episodes remain key strategies. In addition to these
malaria control strategies, there has been renewed interest
in developing transmission-blocking vaccines (TBVs). While
TBVs do not protect against clinical disease, they aim to
reduce the infectiousness of mosquitoes thereby interrupting
transmission (3, 4). The concept of a TBV was first demonstrated
in early experiments in the late 1950s (5) and later in
1976 (6, 7) where reduced infectivity of gametocytes was
demonstrated following immunization of avian hosts with
inactivated gametocytes and gametes. Further experiments aimed
to identify the targets of this transmission-reducing immunity
by utilizingmurinemonoclonal antibodies to immunoprecipitate
radioisotope-labeled female gametes (8, 9). The first TBV
candidate antigens, Pfs25, Pfs230, and Pfs48/45 were thus
identified, so named due to their observed molecular weight
after separation by SDS-PAGE. Functional characterization
of the Pfs230 and Pfs48/45 proteins has shown them to
be essential for male gamete fertility and zygote formation
(10, 11) while Pfs25 plays a role in ookinete to oocyst
transition (9, 12).
Unlike Pfs25, which is expressed on the surface of activated
female gametes and ookinetes post-fertilization in the mosquito
midgut, Pfs230, and Pfs48/45 are expressed pre-fertilization
in the mature gametocyte stages (13, 14) that are present in
peripheral circulation awaiting uptake during a mosquito blood
meal. The majority of these circulating gametocytes, however,
are destroyed by the host immune system prior to transmission
thus antigens present on the surface of the gametocytes are
presented to the immune system (15, 16). Naturally acquired
immune responses to Pfs230 and Pfs48/45 have been detected in
the sera of individuals living in malaria-endemic areas (16–20)
providing evidence that pre-fertilization sexual stage antigens are
immune targets. Additionally, sera from individuals with high
responses to Pfs230 and Pfs48/45 have been shown to exhibit
transmission-reducing immunity (18, 20–23). Such naturally
acquired transmission-reducing immunity (NA-TRI) has also
been recently shown to reduce infectiousness in field settings
(24). Though considered lead vaccine candidates, challenges
in developing immunogenic vaccine constructs for Pfs230 and
Pfs48/45 have delayed their evaluation in clinical trials. Both
proteins contain a cysteine-rich domain whose disulphide-
bonding pattern results in a complex tertiary structure that
presents a challenge for producing properly folded recombinant
protein (25, 26). The mapping of immunodominant epitopes (27,
28) and the development of various platforms for the production
of properly folded Pfs230 and Pfs48/45 (29–32) have aided not
only vaccine design but also seroepidemiological studies.
Several studies have now been carried out across multiple
sites looking at naturally acquired immune responses to
Pfs230 and Pfs48/45 (19, 20, 30, 33, 34) in a bid to improve
our understanding of naturally acquired immunity (NAI)
to sexual stage antigens. Classical indicators of parasite
exposure such as age, transmission setting, malaria transmission
season and parasite prevalence have been evaluated in a
bid to describe the dynamics of sexual stage immunity.
Discrepancies exist, however, in the observed associations
of the aforementioned factors and seroprevalence of
antibodies to sexual-stage antigens. For instance, there is
no consensus on the impact of age on the development
of sexual stage immunity, with some studies showing
an increase in antibody prevalence with age (19, 33, 35)
while other studies show no association with age (16, 36).
Furthermore, while some studies have shown an increase
in prevalence of responses in high transmission settings
in comparison to low transmission settings (19, 34), other
studies report higher responses in low transmission settings
(36). Additionally, varied study designs and sampling
protocols may affect the estimates of seroprevalence
reported, making it difficult to provide an estimate of
how common responses to sexual stage antigens are in
the population.
Rationale
A better understanding of transmission-reducing immunity
can offer important insights for the design, assessment and
implementation of TBVs. This is of particular importance
as though Pfs48/45 and Pfs230 are currently the most
widely evaluated pre-fertilization TBV candidate antigens,
evidence for the role of other antigens in the acquisition
of NA-TRI (20, 36) would drastically increase the number
of candidate antigens for evaluation. Understanding the
dynamics of NA-TRI can provide important insights into the
prioritization of candidate antigens for clinical testing. This
work aims at providing a description of the prevalence of
antibodies to sexual stage antigens and factors influencing
sexual stage immune responses by analyzing responses to Pfs230
and Pfs48/45.
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Objectives
Our study investigates naturally acquired transmission-reducing
immunity in malaria-endemic populations in Africa. Specifically,
it aims to:
a. Describe the prevalence of antibodies to the widely studied
gametocyte antigens Pfs230 and Pfs48/45.
b. Identify factors associated with the acquisition of naturally
acquired transmission-reducing immunity.
c. Describe the dynamics of naturally acquired transmission
reducing immunity.
Research Question
This systematic review and meta-analysis aims to address the
question “What is the seroprevalence and, at a population level,
what are the factors that influence the development of naturally
acquired anti-gametocyte immune responses in individuals living
in falciparum-malaria endemic areas in Africa?”
METHODS
We performed a systematic review of studies of naturally
acquired Plasmodium falciparum transmission-reducing
immunity in Africa that reported the prevalence of antibodies
to the widely studied gametocyte antigens Pfs230 and Pfs48/45.
We followed the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) guidelines to conduct our analyses
(37) and report our results according to the PRISMA (Preferred
Reported Items for Systematic Reviews and Meta-Analyses)
guidelines (38) (Supplementary Table 1). The study protocol is
registered on PROSPERO (number CRD42019126701).
Study Design
We considered cross-sectional and longitudinal studies in our
analyses. The inclusion of longitudinal studies that were spread
over the malaria transmission season allowed for examination
of transmission season as a potential modulator of sexual
stage immune responses. We excluded hospital-based studies as
they potentially would confound our results since these studies
recruited participants with acute malaria infection. Our goal was
to describe seroprevalence in a way that was generalizable at a
population level.
Participants
The study population investigated was individuals living in
malaria-endemic areas in Africa. We included studies recruiting
both children and adults to be as representative as possible
and our outcome was the development of antibodies to Pfs230
and/or Pfs48/45.
Search Strategy
The search strategy was based on the keywords: (pfs230 OR
pfs48 OR pfs45) AND (antibodies OR immunity OR response)
AND (plasmodium OR falciparum OR malaria). Reference lists
of relevant studies were also searched for additional studies.
Data Sources, Studies Selection, and Data
Extraction
Data Sources
Databases searched were MEDLINE/PubMed, SCOPUS, Web of
Science, African Index Medicus, Embase, and African Journals
Online from 1st February 2019 to 31st March 2019.We contacted
study authors to provide prevalence data where it was not
possible to extract the information directly from the published
source. Alternatively, if raw data were available in public
repositories, we used these data to estimate seroprevalence.
Study Selection
Criteria for study inclusion were: (1) studies reporting data
from Africa (2) studies that measured antibody responses to
Pfs230 and/or Pfs48/45. Studies from all years and written in
all languages were included. Studies were excluded if: (1) they
only reported antibody responses to non-falciparum antigens (2)
they were vaccine, drug, or any other interventional trial (3) they
analyzed responses in pregnant women (4) they did not measure
antibody responses quantitatively (5) they sampled fewer than 30
participants (where studies recruited both children and adults,
studies with fewer than 30 participants in each category were
excluded). Where two studies had analyzed the same cohort,
we considered the study where seroprevalence was evaluated in
relation to a larger number of variables that were to be tested in
the analyses.
Data Extraction
Data on seroprevalence to Pfs230 and/or Pfs48/45 were extracted
from the studies using a standardized data extraction form.
The data extraction form was developed to capture information
on the study site, transmission intensity of the study site,
season during which the participants were recruited, asexual
and sexual parasite prevalence, study population, study design,
age categories investigated, type of immunoassay used to
detect immune responses, antigen coating concentration, serum
dilution, source of antigen for the immunoassay, type of negative
controls used, and method used to assess seropositivity.
Data Analysis
Heterogeneity between studies was assessed using the Cochran’s
Q, I2, and H statistics with I2 values of <30, 30–75, and
>75% as cutoffs for low, moderate, and high estimates
of heterogeneity, respectively. Sources of heterogeneity were
explored through moderator analysis using sub-grouping and
meta-regression. Conservative p-values were calculated using
the “Knapp-Hartung” method. Additionally, we adjusted p-
values for multiple comparisons using the Benjamini and
Hochberg correction (39). We calculated the change in
heterogeneity observed after each univariable analysis using the
formula [(overall heterogeneity – residual heterogeneity/overall
heterogeneity) ∗ 100].
Variables explored in the meta-regression included: age group
(broadly categorized as children [0–17 years of age] vs. adults
[≥18 years of age]), parasite prevalence, antigen source for
immunoassay (recombinant protein vs. gametocyte extract),
antigen coating concentration used in the immunoassay, and
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seropositivity cut-off (2 or 3 standard deviations above the
antibody reactivity of malaria naïve individuals or seronegative
individuals identified using maximum likelihood methods to
define Gaussian populations of low and high responders). Where
a study reported seroprevalence for age-categories that slightly
overlapped our pre-defined age categories (i.e., children 0–19
years of age or adults >16 years of age) and data were not
available to reanalyze the age-category, we used the original
study’s defined age categories for children and adults in our
analyses. For parasite prevalence, we used microscopy-based
estimates as that was the parasite detection method used by
majority of the studies.
To infer transmission intensity at the time of sampling in
a uniform way across studies, we used data from the study by
Snow et al. collected from across Africa from the early 1900s
to 2015 that reported the predicted parasite rate standardized
for 2–10-year olds (PfPR2−10) (40). We used previously defined
endemicity cut-offs (41) to categorize study sites as either
hypoendemic; PfPR2−10 ≤ 10%, mesoendemic; PfPR2−10 > 10–
50% or hyperendemic PfPR2−10 > 50%. Information on the
study site from where participants were sampled was then used
to define the site’s administrative region which was then used to
guide the estimation of the PfPR2−10 for that site.
For longitudinal studies, the seroprevalence estimates
reported at the separate cross-sectional surveys over the follow-
up period were combined to give an overall estimate. Where
the data were seasonally spaced, each cross-section carried out
at either the dry or the rainy season was considered separately
in the univariable analysis. However, where a study measured
responses at the peak and at the end of the rainy season, these
data were pooled and analyzed as responses measured in the
rainy season.
RESULTS
Flow Diagram of Studies Retrieved for the
Review
Five hundred twenty-five potentially relevant studies were
identified from the literature search, 205 of these were unique
studies and these were then screened by title and abstract.
From the screen, 34 studies were deemed to contain relevant
information and after full-text evaluation and assessment against
our inclusion criteria, 12 studies were included in the systematic
review and meta-analysis. A summary of the selection process is
provided in Figure 1.
Study Selection and Characteristics
The 12 studies were carried out across 17 study sites, majority
of which were in West Africa (Burkina Faso, Senegal, Gabon,
Cameroon, Ghana, and Mali) with only one study site in
East Africa (Tanzania) and two study sites in Southern Africa
(Zimbabwe) (Table 1). Ten articles (from 15 study sites)
measured responses to Pfs230 and nine articles (13 study sites)
measured responses to Pfs48/45. Six studies were longitudinal
studies spread over the malaria transmission season with all but
one measuring responses to both Pfs230 and Pfs48/45. Studies
predominantly used ELISA as the immunoassay with only one
study measuring responses using protein microarrays.
Pfs230
Seroprevalence
Ten studies from across 15 study sites in Africa analyzed
immune responses to Pfs230. The range of seroprevalence
estimates was quite wide, ranging from 6% reported by Stone
et al. in Soumousso and Dande villages, Burkina Faso (20)
to 72% reported by Amoah et al. (34) (Figure 2). Significant
heterogeneity was observed between the studies (I2 = 97%; 95%
CI: 96–98%; p< 0.01) therefore, a pooled prevalence estimate was
not calculated.
Factors Associated With Reported Seroprevalence to
Pfs230
We sought to explore how differences in the study population
as well as in the immunoassay protocol employed affected
reported seroprevalence to Pfs230 using meta-regression.
Additionally, we tested whether the variables explored
explained the between-study heterogeneity observed. The
data presented in Table 2 show the results of a univariable
analysis. Compared to children, adults were associated
with higher seroprevalence estimates (β coefficient 0.21,
95% CI: 0.05–0.38, p = 0.042). On the other hand, higher
asexual parasite and gametocyte prevalence were associated
with lower seroprevalence estimates, however, neither of
these associations was statistically significant. Similarly,
transmission intensity and sampling season (dry season
vs. rainy season) were not significantly associated with
seroprevalence estimates.
Of the methodological variables tested, in the six studies that
used recombinant protein as the source of antigen (19, 20, 34, 35,
44, 45), studies using 1µg/ml coating concentration of antigen
in the immunoassay were associated with higher seroprevalence
estimates (β coefficient 0.26, 95% CI: 0.09–0.43, p = 0.042).
Moreover, compared to studies that used a seropositivity cut-
off of 2 standard deviations (SD) above the mean response of
seronegative individuals, studies that used a cut-off of 3 SD
were associated with lower seroprevalence estimates (β coefficient
−0.22, 95% CI: −0.37 to −0.06, p = 0.042). Though modestly
significant (p = 0.07), antibody detection using the microarray
platform was associated with higher seroprevalence estimates
to Pfs230 (β coefficient 0.31, 95% CI 0.08, 0.55) in comparison
to studies using indirect ELISA. Source of antigen (gametocyte
extract vs. recombinant protein) was not significantly associated
with seroprevalence estimates. Due to the limited number of
studies included in the analysis and the fact that not all the
variables were reported for each study, we did not attempt further
multivariable meta-regression.
When we analyzed the degree of heterogeneity explained
by the variables tested, none of the variables resulted in
a decrease in residual heterogeneity below 90% precluding
calculation of a pooled seroprevalence estimate. This was
further confirmed by sub group analyses using age group,
antigen coating concentration and seropositivity cut-off as
variables (Supplementary Figures 1–3) where the heterogeneity
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FIGURE 1 | Consort diagram showing the selection of studies to include in the systematic review and meta-analysis. Reasons for exclusion are included at each step.
*Reasons for exclusion: six studies measured immune responses semi-quantitatively (four of these in the same population), 11 studies had a sample size of < 30, five
studies were healthcare facility-based studies (i.e., primary care facilities or hospitals).
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TABLE 1 | Characteristics of studies included in the systematic review and meta-analysis.
Study
(Reference)
Year Country Region of
study sitec
Sample
size
Age group
(years)
Antigen
detected
Seasonality
tested (Y/N)
Assay Seropositivity
cut-off
Negative
controld
Selective
recruitmente
Amoah et al. (34)a 2018 Ghana
(Abura)
Central 65 6–12 Pfs230 No ELISAR 2 SD Naïve No
Amoah et al. (34)a 2018 Ghana
(Obom)
Greater Accra 75 6–12 Pfs230 No ELISAR 2 SD Naïve No
Lamptey et al. (35) 2018 Ghana Greater Accra 338 2–65 Pfs230 Yes ELISAR 3 SD Test sample No
Stone et al. (20)b* 2018a Burkina Faso Hauts-
Bassins
33 5–14 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample Yes
Stone et al. (20)b* 2018b Burkina Faso Centre-Nord 38 2–10 Pfs230 and
Pfs48/45
No ELISA 3 SD Test sample Yes
Stone et al. (20)b* 2018 Cameroon Centre 140 5–16 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample Yes
Bansal et al. (42) 2017 Zimbabwe Mashonaland
Central
181 6–14 Pfs48/45 No ELISAR 2 SD Naïve No
Paul et al. (43) 2016 Zimbabwe Manicaland 150 6–16 Pfs48/45 No ELISAR 2 SD Naïve No
Ateba-Ngoa et al. (44)b 2016 Gabon Moyen -
Ogooue
286 3–50 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample No
Jones et al. (19)b 2015 Burkina Faso Nord 200 5–16 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Jones et al. (19)b 2015 Ghana Greater Accra 108 5–17 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Jones et al. (19)b 2015 Tanzania Tanga Region 202 3–15 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Skinner et al. (33)b 2015 Mali Koulikoro 3
and Bamako
225 2–25 Pfs230 and
Pfs48/45
Yes MicroarrayR 2 SD No
Template
No
Miura et al. (45) 2013 Mali Kayes 2 45 18–60 Pfs230 No ELISAR 3 SD Naïve No
Ouedraogo et al. (24)b* 2018 Burkina Faso Centre-Nord 128 1–55 Pfs230 and
Pfs48/45
Yes Two-site
ELISAGe
3 SD Naïve No
Ouedraogo et al. (16)a 2011 Burkina Faso Centre-Nord 296 1–>20 Pfs230 and
Pfs48/45
Yes Two-site
ELISAGe
2 SD Naïve No
Van der Kolk et al. (46) 2006 Cameroon Centre 236 5–14 Pfs230 and
Pfs48/45
No Two-site
ELISAGe
2 SD Naïve No
aSeroprevalence data provided by authors upon request.
bSeroprevalence data calculated from data provided by original authors, or from data available on public repositories.
b*Citation also includes citation of repository from which data was retrieved.
cAdministrative region of study site from which participants were drawn, this was used infer predicted parasite prevalence rates standardized in 2 – 10-year olds (PfPR2−10 ) that was then used to assign transmission intensity at the time
of sampling.
dNegative control refers to the comparator used to assign seropositivity in the immunoassay. Naïve – malaria naïve volunteers; Sample – a proportion of statistically – defined seronegative individuals; No template - a ‘no DNA control’
used to detect reactivity to the expression vector used to produce protein for the array.
eSelective recruitment refers to studies that only recruited parasite positive individuals for antibody measurements.
RRecombinant protein; Gegametocyte extract.
SD, standard deviation.
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FIGURE 2 | Forest plot of the prevalence of antibodies to Pfs230 in endemic sera from Africa. Seropositive individuals were defined as study participants with an
antibody reactivity above a set cut-off defined from seronegative individuals as measured in an immunoassay.
between studies in each category was still greater than our
threshold of 75%.
Pfs48/45
Seroprevalence
A total of 9 studies carried out over 13 study sites measured
immune responses to Pfs48/45. The range of seroprevalence
estimates reported was 0% from Stone et al.’s study sites in
Burkina Faso (20) to 64% reported by Paul et al. from their
study in the Makoni district in Zimbabwe (43). As with Pfs230,
there was significant heterogeneity between the studies, I2 =96%
(95% CI: 95–97%), and hence no pooled estimate was calculated
(Figure 3).
We also carried out a pairwise comparison of seroprevalence
estimates between Pfs230 and Pfs48/45 in five studies where
both antigens were tested using the same protocol per study.
Some studies reported higher responses to Pfs230 and others
to Pfs48/45, and therefore we found no consistent pattern
to suggest higher seroprevalence estimates to either antigen
(Supplementary Figure 4).
Factors Associated With Reported Seroprevalence to
Pfs48/45
As with Pfs230, we assessed how differences in the study
population and in the immunoassay protocol affect reported
seroprevalence to Pfs48/45 using meta-regression. From the
univariable analysis, adults were associated with modestly higher
seroprevalence estimates (β coefficient 0.07, 95% CI:−0.12–0.27)
as with Pfs230, however, this was not statistically significant (p
= 0.49). Higher parasite prevalence was associated with lower
seroprevalence estimates, and this was statistically significant for
gametocyte prevalence (β coefficient −0.003, 95% CI: −0.005–
0.002, p = 0.003). Similar to Pfs230, transmission intensity
and sampling season were not significantly associated with
seroprevalence estimates.
Type of immunoassay was significantly associated with
seroprevalence estimates as higher seroprevalence was
reported where microarray was used in comparison to indirect
ELISA (β coefficient 0.36, 95% CI: 0.15–0.56, p = 0.016).
Furthermore, studies using 1µg/ml coating concentration
of antigen in the immunoassay were associated with higher
seroprevalence estimates (β coefficient 0.30, 95% CI: 0.06–
0.54, p = 0.043) while studies that used a seropositivity
cut-off of 3 SD were associated with lower seroprevalence
estimates (β coefficient −0.26, 95% CI: −0.39, −0.12, p
= 0.003). We did not have statistical power to carry out
multivariable meta-regression.
Gametocyte prevalence explained a high degree of
heterogeneity (i.e., 25%), resulting in a residual heterogeneity
of 71%, suggesting that seroprevalence was lower at higher
gametocyte prevalence.We then decided to carry out a sub-group
analysis of the four studies reporting gametocyte prevalence data
(16, 19, 20, 24) with grouping by gametocyte prevalence coded as
a categorical variable: <10, 10–50%, and >50% (Figure 4). We
found that the observed association of decreased seroprevalence
with increased gametocyte prevalence was highly influenced
by Stone et al.’s study, where 99% of children sampled were
gametocyte positive but reported low seroprevalence to Pfs48/45.
This was confirmed by sensitivity analysis carried out in the
absence of the Stone et al. study (Supplementary Table 2).
Therefore, we do not have strong evidence of an association
between seroprevalence and gametocyte prevalence when
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TABLE 2 | Univariable meta-regression analysis of factors influencing reported seroprevalence to Pfs230.
No. of studies
(No. of Sites)
Coefficient (β) Lower CI Upper CI p-value* Residual I2 I2 change (%)
Age
Children (ref.) 10 (14)
Adults 6 (6) 0.21 0.05 0.38 0.04 95.36 2.09
Asexual parasite
prevalence
6 (10) −0.001 −0.005 0.002 0.51 95.37 2.08
Gametocyte prevalence 4 (8) −0.002 −0.004 0.001 0.38 92.54 4.50
Transmission intensity
Mesoendemic (ref.) 7 (8)
Hyperendemic 6 (7) −0.06 −0.23 0.11 0.51 96.18 1.25
Season
Dry (ref.) 6 (9)
Rainy 5 (7) 0.07 −0.12 0.27 0.51 96.24 1.19
Assay
ELISA (ref.) 6 (11)
Microarray 1 (1) 0.31 0.08 0.55 0.07 95.29 2.17
Two-site ELISA 3 (3) 0.12 −0.06 0.29
Antigen
Gametocyte extract (ref.) 3 (3)
Recombinant protein 7 (12) −0.06 −0.25 0.13 0.51 96.31 1.12
Antigen concentration+
0.1µg/ml (ref.) 3 (7)
1µg/ml 3 (4) 0.26 0.09 0.43 0.04 93.52 3.98
Seropositivity cut-off
2 SD (ref.) 4 (5)
3 SD 6 (10) −0.22 −0.37 −0.06 0.04 95.16 2.30
*p-values adjusted using the Benjamini and Hochberg correction for multiple testing; values in bold p < 0.05.
+ Antigen concentration was only tested for studies using recombinant protein as antigen source.
CI, confidence interval; SD, standard deviation.
FIGURE 3 | Forest plot of the prevalence of antibodies to Pfs48/45 in endemic sera from Africa. Seropositive individuals were defined as study participants with an
antibody reactivity above a set cut-off defined from seronegative individuals as measured in an immunoassay.
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FIGURE 4 | Forest plot of the prevalence of antibodies to Pfs48/45 in endemic sera from Africa grouped by gametocyte prevalence. Seropositive individuals were
defined as study participants with an antibody reactivity above a set cut-off defined from seronegative individuals as measured in an immunoassay. 1Participants
samples during the dry season; 2Participants sampled during the rainy season.
comparing these studies. Although assay, antigen coating
concentration and seropositivity were statistically significant
predictors in the meta-regression, sub-group analysis by assay,
antigen coating concentration or seropositivity cut-off did not
reduce the heterogeneity to below 75% as seen in Table 3 and
Supplementary Figures 5–7.
Risk of Bias
As the studies included in these analyses were observational
and non-comparative, we did not feel it appropriate to test
for publication bias. We observed that studies reporting low
prevalence were just as likely to report their results as
studies reporting a high prevalence of antibodies to Pfs230
and Pfs48/45 as neither of these outcomes are linked to a
statistically significant result that would be considered desirable
or undesirable.
DISCUSSION
With a renewed interest in developing a malaria TBV, a better
understanding of naturally acquired immunity (NAI) to malaria
is required to aid vaccine design, evaluation and implementation.
We carried out a systematic review and meta-analysis of studies
that evaluated naturally acquired immune responses to the widely
study vaccine candidate antigens Pfs230 and Pfs48/45 in African
populations. By combining results from different studies carried
out across the continent, we aimed to define the prevalence of
NAI to the two well-characterized sexual stage antigens. Our
analysis largely focused on age, transmission intensity, season
and parasite prevalence as markers of malaria exposure, and
sought to describe their association with seroprevalence to Pfs230
and Pfs48/45 at the population level.
When all studies were examined in combination, the reported
seroprevalence to both antigens ranged from 0% (20) to 64%
(45) for Pfs48/45 and from 6% (19) to 72% for Pfs230 (34).
Between-study heterogeneity did not allow for the pooling of
studies to arrive at a single reliable seroprevalence estimate
for either antigen. We therefore sought to explore potential
factors affecting seroprevalence and their possible contribution
to the heterogeneity observed. Factors we considered were age,
transmission setting, sampling season and parasite prevalence.
Furthermore, noting that there was considerable variation in
study design, we also considered methodological factors in
the analysis.
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TABLE 3 | Univariable meta-regression analysis of factors influencing reported seroprevalence to Pfs48/45.
No. of Studies
(No. of Sites)
Coefficient (β) Lower CI Upper CI p-value Residual I2 I2 change (%)
Age
Children (ref.) 9 (13)
Adults 4 (4) 0.07 −0.12 0.27 0.49 94.90 −0.18
Asexual parasite
prevalence
4 (8) −0.003 −0.006 0.0003 0.11 91.41 3.96
Gametocyte prevalence 4 (8) −0.003 −0.005 −0.002 0.003 70.82 25.24
Transmission intensity
Hypoendemic (ref.) 1(1)
Mesoendemic 5 (6) −0.47 −0.89 −0.06 0.11 93.91 0.87
Hyperendemic 5 (6) −0.38 −0.80 0.04
Season
Dry (ref.) 4 (6)
Rainy 6 (8) 0.07 −0.09 0.24 0.47 93.12 1.70
Assay
ELISA (ref.) 5 (9)
Microarray 1 (1) 0.36 0.15 0.56 0.016 91.99 2.89
Two-site ELISA 3 (3) 0.09 −0.07 0.24
Antigen
Gametocyte extract (ref.) 3 (3)
Recombinant protein 6 (10) −0.01 −0.19 0.17 0.91 94.91 −0.19
Antigen concentration+
0.1µg/ml (ref.) 3 (7)
1µg/ml 2 (2) 0.30 0.06 0.54 0.043 92.65 2.20
Seropositivity cut-off
2 SD (ref.) 5 (5)
3 SD 4 (8) −0.26 −0.39 −0.12 0.003 91.38 3.54
*p-values adjusted using the Benjamini and Hochberg correction for multiple testing; values in bold p < 0.05.
+Antigen concentration was only tested for studies using recombinant protein as antigen source.
CI, confidence interval; SD, standard deviation.
The influence of age on NAI to sexual stage antigens has been
the subject of much debate with some studies showing no age-
dependent acquisition of immune responses (16, 36, 47) while
others demonstrate increasing antibody prevalence with age. NAI
to asexual stage antigens, for instance, merozoite surface proteins
(48, 49) or the infected erythrocyte protein family Plasmodium
falciparum erythrocyte membrane protein 1 (50), has been more
extensively studied than immunity to sexual stage antigens and
reports indicate that immune responses increase with age. This
may reflect the time taken to acquire a repertoire of antibodies,
particularly to clonally variant antigens such as PfEMP1, and/or
the gradual acquisition of long-lived plasma cells and memory
B cells with repeated parasite exposure (49, 51). This meta-
analysis found a modest association between increased age and
an increase in the prevalence of antibodies to the gametocyte
antigens Pfs230 and Pfs48/45 which was statistically significant
for Pfs230 (Table 2). Some studies have argued that immune
responses to sexual stage antibodies are short-lived [potentially
due to a largely T-cell independent response (52)] and reflect
recent rather than cumulative exposure to gametocytes (16, 36).
Though not conclusive, this analysis suggests that there may be
a case for long-lived responses to sexual stage antigens. Indeed,
Ouedraogo et al. in their recent study found higher prevalence
and density of antibodies to Pfs230 and Pfs48/45 in adults
which positively correlated with higher transmission-reducing
activity (24).
Our combined analysis did not find a definitive association
between sampling season and seroprevalence to Pfs230 or
Pfs48/45, though there was a trend toward higher seroprevalence
during the rainy season. In the individual studies considered in
the analysis (16, 19, 24) boosting of responses to gametocyte
antigens following the malaria transmission season associated
with increased seroprevalence in responses to both antigens.
Boosting of responses to pre-fertilization sexual stage antigens
during natural malaria infection is an argument put forth in
favor of prioritizing antigens such as Pfs230 and Pfs48/45 for
TBV design (29, 30, 33). Maintaining high titers of transmission-
reducing responses would be essential in reducing malaria
transmission potential. The study by Ouedraogo et al. (24) that
directly assessed the impact of NAI to Pfs230 and Pfs48/45 on
infectiousness to mosquitoes found decreased infectiousness to
mosquitoes during the malaria transmission season that also
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coincided with boosted responses to the two antigens. This
observation may provide evidence to support natural boosting of
TBV responses.
In addition to looking at age and season, we also evaluated the
relationship between transmission intensity and seroprevalence.
Though seroprevalence estimates in individual studies
conducted across multiple study sites described an increase
in seroprevalence with increased transmission settings, we were
not able to demonstrate this in our meta-analysis. Likewise,
we did not observe an association between asexual parasite
or gametocyte prevalence and seroprevalence to either Pfs230
or Pfs48/45.
Substantial heterogeneity between studies persisted even after
sub-group analysis by our pre-specified variables relating to
malaria exposure, and so we also investigated the contribution of
methodological variability to the observed heterogeneity. Studies
differed in their source of antigen, choice of immunoassay, assay
protocol and seropositivity cut-off determination. Early studies
of NAI to Pfs230 and Pfs48/45 relied on whole antigen for the
determination of immune responses owing to the difficulties in
producing recombinant protein for analysis. Assays with whole
antigen involve a two-site ELISA where an epitope-targeted
monoclonal antibody is used to “capture” the target antigen
for detection by antibodies present in the immune sera. Such
assays, however, are reportedly less sensitive (19, 30) which could
lower seroprevalence estimates. In our analysis, however, we did
not observe an influence of antigen source on seroprevalence.
We did, however, find that type of immunoassay influenced
seroprevalence with seroprevalence measured using protein
microarray reporting higher results than either indirect ELISA or
two-site ELISA. This is likely due to the greater dynamic range
afforded by microarray (53) that may allow better distinction
between seropositive and seronegative individuals. We believe
that the field will gradually move to high-throughput multiplex
methods such as microarray or Luminex, although there will
remain a place for ELISAs when large populations are examined
for single-antigen responses.
We found that studies using a lower antigen coating
concentration reported lower seroprevalence estimates.
Seroprevalence to sexual stage antigens is lower than to asexual
stage antigens (23, 54), possibly due to lower immunogenicity of
these antigens or a higher ratio of circulating asexual parasites
to gametocytes (33). For this reason, lower antigen coating
concentration may reduce assay sensitivity, thus it is paramount
that studies optimize antigen coating concentration and serum
dilution combinations prior to measuring immune responses.
Subsequent to measuring immune responses, studies need to
clearly define seronegative and seropositive participants to
estimate seroprevalence. Typically, this is done by defining
cut-offs based on either two or three standard deviations (SD) of
the mean antibody responses in malaria naïve individuals or in
a statistically-defined population of low responders. We found
that studies using a 3 SD cut-off reported lower seroprevalence,
potentially a reflection of the higher stringency in comparison to
a 2 SD cut-off.
What recommendations could be made? First, seropositive
status should be assigned by comparison with a negative control
group (i.e., a population with no malaria exposure). In practice,
the most widely accessible means of doing this is using malaria
naïve European or American sera as a reference. Second, given
the variability of assays, we would recommend the use of
more stringent cut-offs and therefore proposed the mean plus
3 SD of a malaria-naïve population to be used to determine
seropositivity. Establishing a recognized and broadly accepted
“gold-standard” for seropositivity estimates would allow a more
robust comparison between seroepidemiological studies (55).
The increased availability of recombinant protein with defined
conformational properties for use in immunoassays makes the
goal of standardized methodologies more attainable.
Heterogeneity was more evident in the studies reporting
immune responses to Pfs230 than to studies analyzing Pfs48/45.
We hesitate to ascribe this to biological differences between
the two antigens, but rather to persisting heterogeneity
in the studies that analyzed immune responses to Pfs230.
Factors associated with seroprevalence estimates to the two
antigens were largelymethodological rather than epidemiological
underscoring the importance of more standardized methods for
seroepidemiological studies of sexual stage antigens. With the
increasing number of assays performed for seroepidemiology
studies, including but not limited to ELISA, protein microarrays,
Luminex and AlphaScreen, there is need for minimum reporting
parameters to ensure reproducibility, standardization, and to an
extent generalizability of findings. For the analysis of Malaria
Immunoepidemiology Observational Studies (MIOS), Fowkes
et al. (56) have provided reporting standards. In addition
to these standards, we propose that the following minimum
methodological criteria be adopted in lieu of a gold standard:
(1) use of recombinant proteins (with indications of the protein
expression system utilized, protein region targeted—full length
vs. fragments) and if gametocyte/gamete extract is used, a
further analysis of responses to a dominant recombinant antigen
(e.g., Pfs230 and/or Pfs48/45); (2) use of a 3 SD cut-off
to assign seropositivity from a population of naïve controls;
and (3) mention of antigen coating concentration and serum
dilutions used.
Summary of Main Findings
In summary, from the studies analyzed, this systematic review
shows that the range of reported seroprevalence to Pfs230 and
Pfs48/45 varies widely across populations. Of the factors thought
to influence seroprevalence, we found a case for age as an
important determinant of seroprevalence. This is particularly
important as the demonstration that functional TRI likely
involves antigens other than Pfs230 and Pfs48/45 (18, 20, 21, 46),
and with the identification of new TBV candidate antigens (20),
criteria for identifying and prioritizing candidate antigens would
be required. Screening for NAI and selecting antigens which
show increased recognition with age could eliminate antigens
that are simply markers of gametocyte exposure, thus prioritizing
more important candidates for functional characterization.
Though the association was not significant, we did observe
modest evidence for increased prevalence of antibodies to Pfs230
and Pfs48/45 following the malaria transmission season. The
potential for boosting of vaccine-induced immune responses
during natural infection would enhance vaccine efficacy in the
field (57). The extent and implications of this boosting are yet
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to be explored, presenting an interesting question for future
studies. Heterogeneity between studies remained significant even
after assessing study-specific and methodological variation thus
limiting our ability to describe a clear picture of the dynamics of
NAI to sexual stages.
Limitations
As parasite detection in all the studies was by microscopy,
with few studies also reporting PCR prevalence, we were
restricted to using microscopy-based parasite prevalence for
our analysis. The insensitivity of microscopy for parasite
detection (58, 59) would lead to an underestimation of parasite
prevalence. Better estimates of parasite prevalence may offer
novel insights into the association between parasite prevalence
and seroprevalence to sexual stage antigens improving our
understanding of the dynamics of NAI in relation to sexual
stage immunity. Furthermore, few studies currently report
antibody titer in addition to prevalence though titer has been
shown to positively correlate with transmission-reducing activity
(23, 60, 61). Information on antibody titer can help generate
useful information on the impact of naturally acquired sexual-
stage immunity on malaria transmission and this should be
considered in future studies.
Another limitation was that our search revealed only a few
studies looking at naturally acquired immunity to sexual stage
antigens which could limit the generalizability of our results.
Study designs were also varied between studies complicating
attempts to pool the studies in a meta-analysis to arrive at an
overall seroprevalence estimate. While we were able to identify
potential sources of heterogeneity in a univariable analysis,
we could not further test the combined significance of the
associated variables.
Conclusions
The combined analysis presented here showed that antibody
responses to sexual stage antigens are identified in most studies
conducted, suggesting that immunity to Pfs230 and Pfs48/45
is acquired following exposure to malaria parasites. Variability
in study design and methodological differences contributed
to significant between-study heterogeneity that was not fully
addressed by the variables we examined in this analysis.
This highlights the importance of harmonized protocols for
carrying out and reporting seroepidemiological studies to enable
comparability across different settings. Agreed guidelines for
reporting seroepidemiological studies would be valuable for
sexual antigens and could be based on the comprehensive set of
criteria, MIOS, proposed by Fowkes et al. (56).
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